Personalis (NASDAQ:PSNL) Given New $16.25 Price Target at BTIG Research

Personalis (NASDAQ:PSNL) had its price target increased by BTIG Research from $11.00 to $16.25 in a report published on Monday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

Several other brokerages have also commented on PSNL. Morgan Stanley raised their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. TD Cowen reissued a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.25.

Personalis Stock Down 13.3%

NASDAQ:PSNL opened at $13.34 on Monday. The firm’s fifty day simple moving average is $11.09 and its 200 day simple moving average is $8.94. The stock has a market cap of $1.40 billion, a P/E ratio of -13.08 and a beta of 2.24. Personalis has a twelve month low of $3.84 and a twelve month high of $16.39.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. On average, analysts expect that Personalis will post -1.07 EPS for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This represents a 29.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 435,032 shares of company stock valued at $5,599,929. 4.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Personalis in the fourth quarter worth $31,000. Legal & General Group Plc purchased a new stake in shares of Personalis in the second quarter worth $30,000. BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Personalis during the fourth quarter valued at $82,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Key Stories Impacting Personalis

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Tempus AI’s acquisition gives Personalis shareholders a defined exit price of $16.25 per share, which is above the current trading level and reflects a premium to prior prices. Article Title
• Positive Sentiment: The deal could expand Personalis’ reach through Tempus’ AI-enabled precision oncology platform, supporting longer-term strategic value for the business. Article Title
• Neutral Sentiment: BTIG raised its price target on Personalis to $16.25 and kept a buy rating, signaling analyst confidence in the valuation implied by the acquisition. Article Title
• Negative Sentiment: Multiple shareholder-rights law firms have announced investigations into whether the Tempus deal delivers a fair price, raising the possibility of legal challenges or added transaction uncertainty. Article Title
• Negative Sentiment: Needham downgraded Personalis from buy to hold, adding to a more cautious tone around the stock despite the takeover announcement. Article Title

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.